Department of Surgery and Cancer, Division of Cancer, Imperial College London, Garry Weston Centre, Hammersmith Hospital, Du Cane Road, London W12 0NN, UK.
QJM. 2011 Feb;104(2):89-96. doi: 10.1093/qjmed/hcq206. Epub 2010 Nov 16.
Langerhans cell histiocytosis (LCH) has been previously thought of as a rare illness, but is now increasingly diagnosed as a result of the more intensive investigations of patients with cystic pulmonary disease. In recent years, treatments developed from our new understanding of the molecular biology of malignant disease have been applied to patients with LCH, and responses seen. In this review, we describe the origins, presentation and modern treatment of LCH, showing that there is new hope for patients with this condition.
朗格汉斯细胞组织细胞增生症（LCH）以前被认为是一种罕见疾病，但由于对囊性肺病患者进行了更深入的检查，现在越来越多地被诊断出来。近年来，我们对恶性肿瘤分子生物学的新认识所开发的治疗方法已应用于 LCH 患者，并观察到了疗效。在这篇综述中，我们描述了 LCH 的起源、表现和现代治疗方法，表明这种疾病的患者有了新的希望。
